Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2002

View Archived Issues

New modulators of nuclear hormone receptors covered by BMS patent

Aventis presents novel telomerase-inhibitory antitumor agents

Subtype-selective NMDA antagonists and their use in pain and other CNS disorders

CDK1 inhibitors in early development at Aventis

Abbott reveals novel alphavbeta3 modulators in recent patent

Sankyo describes new antiangiogenic agents with utility in diabetic retinopathy

Merck researchers identify novel gamma-secretase inhibitors for use in AD

Promising safety results reported for CpG-7909 as adjuvant to antitumor vaccination

Safety and efficacy of oral ibandronate in breast cancer-related bone events

Potential use of MEN-10755 in recurrent non-small cell lung cancer

R-115777 in myelodysplastic syndrome

Improved safety profile reported for liposome-encapsulated mitoxantrone in advanced cancer

New data on the tolerability of BBR-3438 in advanced solid tumors

Comparison of lumiracoxib and celecoxib in osteoarthritis of the knee

Preliminary phase III results for LAX-101 in Huntington's disease

ETI-104 reported to be safe and effective in systemic lupus erythematosus

G17DT increases median survival time of patients with advanced pancreatic cancer

Effects of MRA on serum VEGF levels in RA patients

Advexin studied in combination with docetaxel and doxorubicin for advanced breast cancer

Second phase III trial fails to demonstrate MorphiDex's superiority to morphine

Lead tetracycline antibiotic candidate selected at Paratek

Lilly launches Xigris in E.U. for severe sepsis

Inspire plans to file INS-365 Ophthalmic NDA based on existing data

FDA issues approvable letter for Hectorol Capsules sNDA

New class of CpG oligonucleotides with promise for HCV infection

NDA submitted for once-daily Cipro XR in complicated UTIs

Approvable letter for Olux expanded label

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...